Skip to main content
Top
Published in: International Urology and Nephrology 2/2016

01-02-2016 | Nephrology - Original Paper

Predictive modeling using a nationally representative database to identify patients at risk of developing microalbuminuria

Authors: Lorenzo Villa-Zapata, Terri Warholak, Marion Slack, Daniel Malone, Anita Murcko, George Runger, Michael Levengood

Published in: International Urology and Nephrology | Issue 2/2016

Login to get access

Abstract

Purpose

Predictive models allow clinicians to identify higher- and lower-risk patients and make targeted treatment decisions. Microalbuminuria (MA) is a condition whose presence is understood to be an early marker for cardiovascular disease. The aims of this study were to develop a patient data-driven predictive model and a risk-score assessment to improve the identification of MA.

Methods

The 2007–2008 National Health and Nutrition Examination Survey (NHANES) was utilized to create a predictive model. The dataset was split into thirds; one-third was used to develop the model, while the other two-thirds were utilized for internal validation. The 2012–2013 NHANES was used as an external validation database. Multivariate logistic regression was performed to create the model. Performance was evaluated using three criteria: (1) receiver operating characteristic curves; (2) pseudo-R 2 values; and (3) goodness of fit (Hosmer–Lemeshow). The model was then used to develop a risk-score chart.

Results

A model was developed using variables for which there was a significant relationship. Variables included were systolic blood pressure, fasting glucose, C-reactive protein, blood urea nitrogen, and alcohol consumption. The model performed well, and no significant differences were observed when utilized in the validation datasets. A risk score was developed, and the probability of developing MA for each score was calculated.

Conclusion

The predictive model provides new evidence about variables related with MA and may be used by clinicians to identify at-risk patients and to tailor treatment. The risk score developed may allow clinicians to measure a patient’s MA risk.
Literature
1.
go back to reference Anderson GF, Hussey PS, Frogner BK, Waters HR (2005) Health spending in the United States and the rest of the industrialized world. Health Aff (Proj Hope) 24(4):903–914CrossRef Anderson GF, Hussey PS, Frogner BK, Waters HR (2005) Health spending in the United States and the rest of the industrialized world. Health Aff (Proj Hope) 24(4):903–914CrossRef
3.
go back to reference Duncan I (2011) Healthcare risk adjustment and predictive modeling. ACTEX Publications, Inc, Winsted, CT Duncan I (2011) Healthcare risk adjustment and predictive modeling. ACTEX Publications, Inc, Winsted, CT
6.
go back to reference Wharam JF, Weiner JP (2012) The promise and peril of healthcare forecasting. Am J Manag Care 18(3):e82–e85PubMed Wharam JF, Weiner JP (2012) The promise and peril of healthcare forecasting. Am J Manag Care 18(3):e82–e85PubMed
8.
go back to reference Scheven L, Van der Velde M, Lambers Heerspink HJ, De Jong PE, Gansevoort RT (2013) Isolated microalbuminuria indicates a poor medical prognosis. Nephrol Dial Transplant 28(7):1794–1801. doi:10.1093/ndt/gft031 PubMedCrossRef Scheven L, Van der Velde M, Lambers Heerspink HJ, De Jong PE, Gansevoort RT (2013) Isolated microalbuminuria indicates a poor medical prognosis. Nephrol Dial Transplant 28(7):1794–1801. doi:10.​1093/​ndt/​gft031 PubMedCrossRef
9.
go back to reference Yudkin JS, Forrest RD, Jackson CA (1988) Microalbuminuria as predictor of vascular disease in non-diabetic subjects: islington diabetes survey. Lancet 2(8610):530–533PubMedCrossRef Yudkin JS, Forrest RD, Jackson CA (1988) Microalbuminuria as predictor of vascular disease in non-diabetic subjects: islington diabetes survey. Lancet 2(8610):530–533PubMedCrossRef
10.
go back to reference Bakris GL (1996) Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens 5(3):219–223PubMedCrossRef Bakris GL (1996) Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens 5(3):219–223PubMedCrossRef
11.
go back to reference Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, Van Gilst WH, De Zeeuw D, De Jong PE, Prevend Study G (2001) Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249(6):519–526PubMedCrossRef Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, Van Gilst WH, De Zeeuw D, De Jong PE, Prevend Study G (2001) Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249(6):519–526PubMedCrossRef
14.
go back to reference Derhaschnig U, Kittler H, Woisetschlager C, Bur A, Herkner H, Hirschl MM (2002) Microalbumin measurement alone or calculation of the albumin/creatinine ratio for the screening of hypertension patients? Nephrol Dial Transplant 17(1):81–85PubMedCrossRef Derhaschnig U, Kittler H, Woisetschlager C, Bur A, Herkner H, Hirschl MM (2002) Microalbumin measurement alone or calculation of the albumin/creatinine ratio for the screening of hypertension patients? Nephrol Dial Transplant 17(1):81–85PubMedCrossRef
15.
16.
go back to reference Mongkolsomlit S, Rawdaree P, Komoltri C, Tawichasri C, Patumanond J (2012) The development and validation of a risk score for predicting microalbuminuria in type 2 diabetic patients. J Diabetes Mellit 2(2):227–233. doi:10.4236/jdm.2012.22036 CrossRef Mongkolsomlit S, Rawdaree P, Komoltri C, Tawichasri C, Patumanond J (2012) The development and validation of a risk score for predicting microalbuminuria in type 2 diabetic patients. J Diabetes Mellit 2(2):227–233. doi:10.​4236/​jdm.​2012.​22036 CrossRef
17.
go back to reference Moons KG, Harrell FE, Steyerberg EW (2002) Should scoring rules be based on odds ratios or regression coefficients? J Clin Epidemiol 55(10):1054–1055PubMedCrossRef Moons KG, Harrell FE, Steyerberg EW (2002) Should scoring rules be based on odds ratios or regression coefficients? J Clin Epidemiol 55(10):1054–1055PubMedCrossRef
21.
go back to reference Meigs JB, D’Agostino RB Sr, Nathan DM, Rifai N, Wilson PW, Framingham Offspring S (2002) Longitudinal association of glycemia and microalbuminuria: the Framingham offspring study. Diabetes Care 25(6):977–983PubMedCrossRef Meigs JB, D’Agostino RB Sr, Nathan DM, Rifai N, Wilson PW, Framingham Offspring S (2002) Longitudinal association of glycemia and microalbuminuria: the Framingham offspring study. Diabetes Care 25(6):977–983PubMedCrossRef
22.
go back to reference Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H (2010) Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the randomised olmesartan and diabetes microalbuminuria prevention (ROADMAP) study. Diabetologia 53(1):49–57. doi:10.1007/s00125-009-1577-3 PubMedPubMedCentralCrossRef Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H (2010) Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the randomised olmesartan and diabetes microalbuminuria prevention (ROADMAP) study. Diabetologia 53(1):49–57. doi:10.​1007/​s00125-009-1577-3 PubMedPubMedCentralCrossRef
25.
go back to reference Eghan BA Jr, Frempong MT, Adjei-Poku M (2007) Prevalence and predictors of microalbuminuria in patients with diabetes mellitus: a cross-sectional observational study in Kumasi, Ghana. Ethn Dis 17(4):726–730PubMed Eghan BA Jr, Frempong MT, Adjei-Poku M (2007) Prevalence and predictors of microalbuminuria in patients with diabetes mellitus: a cross-sectional observational study in Kumasi, Ghana. Ethn Dis 17(4):726–730PubMed
26.
go back to reference Ganji MR (2013) Albuminuria and management of type 2 diabetes mellitus. Iran J Kidney Dis 7(4):245–248PubMed Ganji MR (2013) Albuminuria and management of type 2 diabetes mellitus. Iran J Kidney Dis 7(4):245–248PubMed
28.
go back to reference National Kidney F (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266 National Kidney F (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266
29.
go back to reference Keane WF (2000) Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 35(4 Suppl 1):S97–S105PubMedCrossRef Keane WF (2000) Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 35(4 Suppl 1):S97–S105PubMedCrossRef
30.
go back to reference Navarro JF, Mora C, Maca M, Garca J (2003) Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 42(1):53–61PubMedCrossRef Navarro JF, Mora C, Maca M, Garca J (2003) Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 42(1):53–61PubMedCrossRef
32.
33.
go back to reference Mojahedi MJ, Bonakdaran S, Hami M, Sheikhian MR, Shakeri MT, Aiatollahi H (2009) Elevated serum C-reactive protein level and microalbuminuria in patients with type 2 diabetes mellitus. Iran J Kidney Dis 3(1):12–16PubMed Mojahedi MJ, Bonakdaran S, Hami M, Sheikhian MR, Shakeri MT, Aiatollahi H (2009) Elevated serum C-reactive protein level and microalbuminuria in patients with type 2 diabetes mellitus. Iran J Kidney Dis 3(1):12–16PubMed
Metadata
Title
Predictive modeling using a nationally representative database to identify patients at risk of developing microalbuminuria
Authors
Lorenzo Villa-Zapata
Terri Warholak
Marion Slack
Daniel Malone
Anita Murcko
George Runger
Michael Levengood
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2016
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-015-1183-x

Other articles of this Issue 2/2016

International Urology and Nephrology 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine